The leading lung cancer & mesothelioma clinical trials group in Australia & New Zealand

About TOGA

The Thoracic Oncology Group of Australasia (TOGA) is a member-based research organisation and lung cancer and mesothelioma charity, representing the full range of professional disciplines involved in caring for patients with lung cancer, clinical trial professionals and consumer representatives.

Introduction Video

TOGA provides a collaborative environment for:

  • respiratory physicians,
  • medical oncologists,
  • radiation oncologists,
  • palliative care specialists,
  • cardiothoracic surgeons,
  • allied health professionals
  • scientists and
  • nurses,

across Australia and New Zealand and internationally to design, conduct and publish clinical trials, and through review of clinical and scientific evidence, provides a cutting-edge educational program to inform best practice care and improve outcomes for lung cancer and mesothelioma patients.

Our charitable donations and fundraising programs support clinical trial activities which help to discover better ways to diagnose, treat and support people with lung cancer.

We want to:

We achieve results by:

Research, collaboration and education

With a membership of leading clinicians and thoracic cancer experts that reaches throughout Australia and New Zealand, our leading priority is design and conduct of clinical trials. 

The questions that we address through our research arise from collaboration between healthcare professionals, researchers and people with thoracic cancers and address real questions that arise in the care of thoracic cancer patients and expand treatment options for people with thoracic cancers by providing access to newer treatments, diagnostics and supportive care.

We also collaborate with laboratory researchers to ensure that we apply the latest findings in our clinical research, and that laboratory research maintains a clinical context.

Finally, we conduct an education program and undertake advocacy to ensure the latest research findings and new treatments are translated into standard practice.